TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28440669

Group type: EXPERIMENTAL
Intervention: Dynamic 4D CTA in the shuttle mode (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flash 4D CTA in the high-pitch mode (Group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard triphasic acquisition protocol (Group C)
Number of subjects: 54
Study: 26863054

Group type: EXPERIMENTAL
Intervention: Spectralis optical coherence tomography (OCT)
Number of subjects: 133
Study: 24495287

Group type: EXPERIMENTAL
Intervention: Verbal autopsy (VA) system as part of the Indian Million Death Study (MDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDS cause-specific mortality fractions (CSMFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDS COD classification system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial physician agreement on COD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reliance on urban or hospital data
Number of subjects: 0
Study: 22113218

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (40 mg triamcinolone acetonide)
Number of subjects: 45
Study: 20511270

Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 46

Group type: COMPARATOR
Intervention: No Checklist
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 46
Study: 17625461

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 12
Study: 15708886

Group type: EXPERIMENTAL
Intervention: lamivudine 150 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 12468950

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.), amoxycillin (1 g b.d.) for 7 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 5 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 7 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 10 days
Number of subjects: 160
Study: 9844762

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA) at a dosage of 3 mg/kg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methotrexate (MTX) at a dosage of 0.15 mg/kg/week
Number of subjects: 103
Study: 8029807

Group type: EXPERIMENTAL
Intervention: 30 mg/day aspirin for seven days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 75 mg/day aspirin for seven days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 150 mg/day aspirin for seven days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 150 mg aspirin/day for one week
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 600 or 1200 mg aspirin (single dose)
Number of subjects: 13
Study: 2925974

Group type: EXPERIMENTAL
Intervention: Experimental intervention (AIDS risk education, cognitive‐behavioral self‐management training, sexual assertion training, development of steady and self‐affirming social supports)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 104
Study: 1079063

Group type: EXPERIMENTAL
Intervention: 51 percent fresh blood (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 22 percent fresh blood (Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 25 percent component therapy (Group 3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Component therapy
Number of subjects: 50
Study: 31298266

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 3598

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 3598
Study: 30715501

Group type: EXPERIMENTAL
Intervention: Intermittent light regime (FLASH20: 20 min/h + 40 min constant light)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intermittent light regime (FLASH40: 40 min/h + 20 min constant light)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (continuous light for 16 h/day)
Number of subjects: 270
Study: 28706169

Group type: EXPERIMENTAL
Intervention: Movie-based nursing intervention program (60-minute sessions, once per week for 10 weeks)
Number of subjects: 60
Study: 26468956

Group type: EXPERIMENTAL
Intervention: High current CD4+ T cell count (>660 cells/mm3)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Twice-per-day dosing regimen
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: High CD4+ T cell counts
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low or intermediate CD4+ T cell counts
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Comparison of effects of adherence on virological suppression between patients with high vs. low or intermediate CD4+ T cell counts
Number of subjects: 133
Study: 24494283

Group type: COMPARATOR
Intervention: Needle retention for 20 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Needle retention for 30 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Needle retention for 45 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Needle retention for 60 min
Number of subjects: 80
Study: 21207256

Group type: EXPERIMENTAL
Intervention: EBV detection using immunohistochemical analysis and PCR
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (42 control biopsies)
Number of subjects: 142
Study: 19719543

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 306
Study: 17906165

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 0
Study: 15041595

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg preoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11338068

Group type: EXPERIMENTAL
Intervention: Antibiophilus (Lactobacillus rhamnosus)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 9429011

Group type: EXPERIMENTAL
Intervention: Running Intensive Tennis Training (RIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 8490250

Group type: EXPERIMENTAL
Intervention: Selective Proximal Vagotomy (SPV)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Selective Vagotomy with Pyloroplasty (SV + PP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Selective Proximal Vagotomy with Pyloroplasty (SPV + PP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unoperated controls
Number of subjects: 38
Study: 3010707

Group type: EXPERIMENTAL
Intervention: Enalapril monotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Enalapril and hydrochlorothiazide combination therapy
Number of subjects: 27
Study: 30036748

Group type: EXPERIMENTAL
Intervention: Thin-ideal images
Number of subjects: 220

Group type: COMPARATOR
Intervention: Average images
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High number of likes
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Low number of likes
Number of subjects: 220
Study: 27060939

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Memory enhancement training (MET)
Number of subjects: 25
Study: 23539433

Group type: EXPERIMENTAL
Intervention: Full-intervention group (grades 1-6)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Late intervention group (grades 5-6)
Number of subjects: 608

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 608
Study: 22912445

Group type: COMPARATOR
Intervention: 1 × 10(7) cfu C. butyricum/kg of diet (CB2)
Number of subjects: 450

Group type: COMPARATOR
Intervention: 3 × 10(7) cfu C. butyricum/kg of diet (CB3)
Number of subjects: 450

Group type: COMPARATOR
Intervention: 10 mg of colistine sulfate/kg of diet (antibiotic)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: C. butyricum
Number of subjects: 450
Study: 18963044

Group type: EXPERIMENTAL
Intervention: ACET (Air Conduction Estimated from Tympanometry) formula based on tympanogram categories B, C2, C1, and A.
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: B tympanogram in one ear
Number of subjects: 3085
Study: 17324008

Group type: EXPERIMENTAL
Intervention: ISA 247 (0.2 mg/kg bid)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ISA 247 (0.3 mg/kg bid)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ISA 247 (0.4 mg/kg bid)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: ISA 247 (mid dose)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 193
Study: 12959960

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11773574

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, half that dose if <12 months)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 8590608

Group type: EXPERIMENTAL
Intervention: Ethanol 0.35 g/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ethanol 0.55 g/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2800986

Group type: EXPERIMENTAL
Intervention: Alfentanil 7 micrograms/kg plus methohexitone plus O2/air (Group A7)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg plus methohexitone plus O2/air (Group A15)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg plus N2O/O2 (Group P, reference group)
Number of subjects: 89
Study: 50014

Group type: EXPERIMENTAL
Intervention: Facilitation treatment approach
Number of subjects: 12

Group type: COMPARATOR
Intervention: Functional treatment approach
Number of subjects: 12
Study: 30932317

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 2.5 × 10^9 CFUs, once daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 304
Study: 30624674

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs) containing 20 mg Fe/d until 6 mo postpartum, and SQ-LNSs for infants from 6 to 18 mo of age (LNS)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Iron (60 mg/d) and folic acid (IFA)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) containing 20 mg Fe/d until 6 mo postpartum
Number of subjects: 1320
Study: 27334706

Group type: EXPERIMENTAL
Intervention: Comet
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Incredible Years
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Cope
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Connect
Number of subjects: 749

Group type: COMPARATOR
Intervention: All programs
Number of subjects: 749
Study: 25455432

Group type: EXPERIMENTAL
Intervention: TAD 2.5mg up-titrated to 5mg OaD for 12 weeks
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: TAD 5mg OaD for 12 weeks
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo (PBO) OaD for 12 weeks
Number of subjects: 590
Study: 23521828

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 332

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 332
Study: 21652683

Group type: EXPERIMENTAL
Intervention: CTDa (cyclophosphamide, thalidomide, and dexamethasone)
Number of subjects: 849

Group type: COMPARATOR
Intervention: MP (melphalan and prednisolone)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: CTDa
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: CTDa and MP
Number of subjects: 849
Study: 19781409

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3690

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 3690
Study: 16673054

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham group (placebo)
Number of subjects: 11
Study: 15155045

Group type: EXPERIMENTAL
Intervention: High-threat/high-efficacy message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11055004

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy
Number of subjects: 0
Study: 9590467

Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg twice daily
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 7822454

Group type: EXPERIMENTAL
Intervention: Non-radioactive reverse dot blot hybridization method for typing HPV
Number of subjects: 72
Study: 3398891

Group type: EXPERIMENTAL
Intervention: Surgery plus interferon (2 X 10(6) IU per square meter of body-surface area, daily for one week, then three times per week for one year)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Surgery plus interferon
Number of subjects: 123
Study: 27148916

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 70
Study: 28873709

Group type: EXPERIMENTAL
Intervention: Yacon syrup (8.74g of FOS/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yacon syrup incorporated in yogurt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 26964180

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 22964266

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT-AS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 42
Study: 20171048

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined autologous and allogenic transfusion (Treatment groups)
Number of subjects: 60
Study: 18369313

Group type: EXPERIMENTAL
Intervention: 50 mg DVS
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 100 mg DVS
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 150 mg DVS
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 200 mg DVS
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 17235475

Group type: EXPERIMENTAL
Intervention: Combination preparation (cinnarizine 20 mg and dimenhydrinate 40 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Betahistine (12 mg betahistinedimesilate)
Number of subjects: 2
Study: 12569119

Group type: EXPERIMENTAL
Intervention: CPP-enriched milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CPP-enriched fermented milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 9
Study: 10831147

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg daily via dry powder inhalation (Rotadisk)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 77
Study: 9279218

Group type: EXPERIMENTAL
Intervention: 2 ppm NO2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 30
Study: 8201610

Group type: EXPERIMENTAL
Intervention: Opioid blockade (naltrexone)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 39
Study: 3310282

Group type: EXPERIMENTAL
Intervention: Ampicillin plus tobramycin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 106

Group type: COMPARATOR
Intervention: No aminoglycoside
Number of subjects: 106
Study: 30166304

Group type: EXPERIMENTAL
Intervention: Patient-centred educational exchange (PCEE) composed of two sessions, one at the bedside before discharge and one by telephone at least 10 days after discharge from hospital in addition to usual care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-centred educational exchange (PCEE)
Number of subjects: 0
Study: 26506952

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PErFecTED prostate artery embolization (PAE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original prostate artery embolization (oPAE)
Number of subjects: 30
Study: 25403238

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1477
Study: 23756297

Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training (SCST)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Illness Management Training (Control)
Number of subjects: 42
Study: 21389938

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (haloperidol)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No delirium
Number of subjects: 68
Study: 18524403

Group type: EXPERIMENTAL
Intervention: Exercise group (five week exercise program including functionally oriented obstacle course, walking exercises, and practice of fall techniques)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 0
Study: 16391172

Group type: EXPERIMENTAL
Intervention: 0.1 mg clonidine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.1‐mg/h nitroglycerin transdermal patch
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 14597946

Group type: EXPERIMENTAL
Intervention: Lisinopril (uptitrated to 20 mg/d)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valsartan (uptitrated to 160 mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 90

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 90
Study: 10759621

Group type: EXPERIMENTAL
Intervention: Mylanta Lemon Twist
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mylanta Cherry Crème
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Maalox MS Cool Mint
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ES Gaviscon
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Extra strength antacids
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Amphogel
Number of subjects: 73
Study: 8752254

Group type: EXPERIMENTAL
Intervention: Oral calcium plus oral clodronate, 400 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral calcium plus oral clodronate, 400 mg/day for 30 days, followed by 60 days of calcium supplement alone (cyclical regimen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral calcium, 1000 mg/day (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous clodronate treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cyclical clodronate treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clodronate (both cyclical and continuous)
Number of subjects: 60
Study: 1561052

Group type: EXPERIMENTAL
Intervention: Chaotic attractors' sequences (Henon, Zaslavskii, Kaplan and Yorke, Lorenz, Gregson, logistic, and Baker transformations)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Random series (10 realizations)
Number of subjects: 141
Study: 4025245

Group type: EXPERIMENTAL
Intervention: Practice group (received information and encouraged to perform coping techniques)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: No-practice group (received information but not encouraged to perform coping techniques)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 31668477

Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 6 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 15 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 30 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 6 mg, 15 mg, 30 mg
Number of subjects: 120
Study: 30525855

Group type: EXPERIMENTAL
Intervention: Symbiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27288381

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen at a dose of 800 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24768120

Group type: EXPERIMENTAL
Intervention: DBS + ODT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Optimal drug therapy (ODT)
Number of subjects: 30
Study: 22573476

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV) 10 mg/d
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus Ezetimibe (RSV/EZT) 10 mg/d
Number of subjects: 262
Study: 20552577

Group type: EXPERIMENTAL
Intervention: Luteinizing-hormone-releasing hormone (LHRH) agonists for ovarian function suppression (OFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 0
Study: 18156478

Group type: EXPERIMENTAL
Intervention: Topical aqueous 2% lignocaine eardrops
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (saline eardrops)
Number of subjects: 63
Study: 15983240

Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study: 14513587

Group type: EXPERIMENTAL
Intervention: Laser therapy combined with ultrasonic subgingival scaling and root planning (SRP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 26
Study: 10097027

Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (chocolate cravers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full-trained subjects (chocolate cravers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (non-cravers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full-trained subjects (non-cravers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (both cravers and non-cravers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full-trained subjects (both cravers and non-cravers)
Number of subjects: 29